Pharmaceutical Research and Manufacturers of America (PhRMA) news and information

An ongoing federal probe indicates there was a deal between the White House and PhRMA that bound both entities to certain commitments before Congress passed the healthcare reform law.
FULL STORY »

Although many providers and drug companies have frozen their compliance with a new federal payment reporting law until regulations are finalized, many devicemakers are busy preparing.
FULL STORY »

Only 13% of U.S. medical schools have a top-rated policy requiring faculty to disclose past or present financial ties with the pharmaceutical industry, even though a new federal law will soon require disclosures of such information publicly, the American Medical Student Association reports.
FULL STORY »

The Food and Drug Administration needs more resources for oversight of products developed and manufactured overseas, FDA Commissioner Dr. Margaret Hamburg said during a House hearing examining the Prescription Drug User Fee Act.
FULL STORY »

Healthcare industry groups are less concerned about the lineup of the newly appointed federal deficit-reduction “super committee” than they are about that team's game plan for Nov. 23.
FULL STORY »

About 10 years ago, a well-known pharmaceutical firm asked Dr. Daniel Carlat to serve on a medical advisory board. This was before the ongoing national explosion of medical-ethics crises, and Carlat at the time was known for working closely with industry.
FULL STORY »

Under the weight of public scrutiny and a turbulent period in the financial lives of tax-exempt associations, many top executives at healthcare-related associations took home less money in 2009 than they did the year before.
FULL STORY »

The wheels of international diplomacy traditionally move slowly, but a recently formed public-private partnership in healthcare between the U.S. and China is taking shape at a relatively quick pace.
FULL STORY »

A pharmacy benefit management trade association is accusing drug manufacturers of initiating a “quiet campaign” to promote bills in 11 state legislatures that would undermine the cost and safety benefits of electronic prescribing.
FULL STORY »